NANOFÁRMACOS

Volver

Resultados 103 resultados LastUpdate Última actualización 26/02/2017 [14:57:00] pdf PDF




Solicitudes publicadas en los últimos 30 días / Applications published in the last 30 days



Página1 de 5 nextPage   Mostrar por página


A method of preparing amorphous solid dispersion in submicron range by co-precipitation

NºPublicación: AU2015295073A1 23/02/2017

Solicitante:
HOVIONE INT LTD

Resumen de: AU2015295073A1

The present invention discloses a method for producing amorphous solid dispersions in a nanoparticulate form, through solvent controlled co-precipitation, using microfluidization/microreaction technology to promote high energy mixing/interaction at a micro and/or molecular level between the streams involved in the process. Feed streams, solvent and anti-solvent, are fed to an intensifier pump at individually controlled rates and forced to interact to micro-and/or nano-scale within a microreactor. The present invention also discloses amorphous solid dispersions obtained by the method of the invention as well as pharmaceutical compositions containing the same.



traducir


 

Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent

NºPublicación: AU2015289504A1 23/02/2017

Solicitante:
BIOCURITY HOLDINGS INC

Resumen de: AU2015289504A1

The present invention is directed to methods for the treatment of cancer with a combination of radiation, cerium oxide nanoparticles and at least one chemotherapeutic agent. Cerium oxide nanoparticles (CONPs) are nanometer-sized crystals of cerium oxide, typically ranging between about one nanometer to about 20 nanometers in longest dimension. The present methods use cerium oxide nanoparticles to enhance radiation-induced and chemotherapy-induced cancer cell death and also reduce the toxicity associated with radiation therapy and chemotherapy



traducir


 

FUCOIDAN NANOGELS AND METHODS OF THEIR USE AND MANUFACTURE

NºPublicación: EP3131534A1 22/02/2017

Solicitante:
MEMORIAL SLOAN KETTERING CANCER CENTER [US]

Resumen de: WO2015161192A1

Described herein are polymeric drug-carrying nanogels that are capable of targeting to P-selectin for the treatment of cancer and other diseases and conditions associated with P-selectin. Furthermore, in certain embodiments, the nanogels presented here offer a drug release mechanism based on acidic pH in the microenvironment of a tumor, thereby providing improved treatment targeting capability and allowing use of lower drug doses, thereby reducing toxicity.



traducir


 

METHODS OF TREATING CANCERS WITH THERAPEUTIC NANOPARTICLES

NºPublicación: EP3131542A1 22/02/2017

Solicitante:
PFIZER [US]

Resumen de: WO2015161272A1

The present disclosure relates in part to methods of treating cancers having a mutation in a Ras gene in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein the nanoparticle composition comprises nanoparticles.



traducir


 

VITAMIN E-BASED NANOCARRIERS FOR DRUG DELIVERY AND METHODS OF MAKING AND USING THE SAME

NºPublicación: EP3131944A1 22/02/2017

Solicitante:
THE CORP OF MERCER UNIV [US]

Resumen de: WO2015161295A1

Vitamin E-based amphiphilic copolymers are disclosed. Compositions containing vitamin E-based amphiphilic copolymers and/or nanocarriers are also disclosed. Methods of making vitamin E-based amphiphilic copolymers and/or nanocarriers and methods of using vitamin E-based amphiphilic copolymers and/or nanocarriers are also disclosed.



traducir


 

NANOCARRIER COMPOSITIONS WITH UNCOUPLED ADJUVANT.

NºPublicación: BR112012029917A2 21/02/2017

Solicitante:
SELECTA BIOSCIENCES INC [US]

Resumen de: MX2012013713A

Disclosed are synthetic nanocarrier compositions with separate adjuvant compositions as well as related methods.



traducir


 

POLYMERIC NANOPARTICLES WITH DEC-205 LIGAND AND CO-ENCAPSULATING AN ANTIGEN SUBJECT TO AN AUTOIMMUNE RESPONSE AND A GLUCOCORTICOID RECEPTOR AGONIST

NºPublicación: WO2017025889A1 16/02/2017

Solicitante:
PFIZER [US]

Resumen de: WO2017025889A1

The present invention provides a nanoparticle comprising a polymeric matrix and a covalently-bound surface-orientated targeting ligand for DEC-205, said polymeric matrix encapsulating an antigen which is the subject of an undesirable immune response and a glucocorticoid receptor agonist. The nanoparticles of the invention can be used to treat autoimmune diseases such as haemophilia A and multiple sclerosis.



traducir


 

METHOD FOR ENCAPSULATING ALLERGENS IN NANOPARTICLES OF CHITOSAN AND ALGINATE FOR REDUCING THE RECOGNITION OF ALLERGENS BY IGE ANTIBODIES WHEN CONDUCTING ALLERGEN-SPECIFIC IMMUNOTHERAPY

NºPublicación: WO2017026915A1 16/02/2017

Solicitante:
SVIRSHHEVSKAJA ELENA VIKTOROVNA [RU]
KASHIRINA ELENA IGOREVNA [RU]
ALEKSEEVA LJUDMILA GENNAD'EVNA [RU]
ZUBOV VITALIJ PAVLOVICH [RU]

Resumen de: WO2017026915A1

The invention relates to the fields of immunology and medicine and concerns the artificial construction of "core/shell"-type micro/nanoparticles containing, in the core thereof, extracts of natural allergens and/or recombinant allergens, conjugated to chitosan, and covered in an additional shell made of sodium alginate. The encapsulated allergens do not bind to IgE antibodies, but rather maintain protein immunogenicity and cause the formation of protective IgGs when administered subcutaneously, intranasally, sublingually, orally or transepidermally. The encapsulated allergens and proteins are intended for performing specific immunotherapy with the aim of inducing a controllable protective humoral IgG-mediated immune response to an allergen which suppresses a pathogenic IgE-mediated immune response. The field of medical application comprises all forms of pollen, food, fungal and common allergies. The biological target of the encapsulated allergens is an adaptive (antigen-specific) immune response including antigen-presenting cells (macrophages, dendritic and B-cells) and T and B cells.



traducir


 

CROSS-LINKED STAR-SHAPED SELF-ASSEMBLED POLYPEPTIDES AND ITS USE AS CARRIERS IN BIOMEDICAL APPLICATIONS

NºPublicación: WO2017025298A1 16/02/2017

Solicitante:
CENTRO DE INVESTIG PRINCIPE FELIPE [ES]

Resumen de: WO2017025298A1

The invention relates to 3-arms star-shaped polypeptides derivatives which are able to self-assemble to form bioresponsive nanometric globular structures with controllable size and shape. These multivalent constructs also present the ability of disassemble under specific physiological conditions and of linking to at least one active agent so that they can be used as carries in biomedical applications.



traducir


 

Cationic lipid

NºPublicación: AU2015300046A1 16/02/2017

Solicitante:
TAKEDA PHARMACEUTICALS CO

Resumen de: AU2015300046A1

The present invention provides: a technique which enables an active ingredient (such as a nucleic acid) to be introduced into many types of cell with excellent efficiency; and a compound used in said technique. The present invention provides a compound represented by formula (1) (in formula (1), each symbol is as defined in the description of the present application) or a salt thereof.



traducir


 

PASSIVATED NANOPARTICLES

NºPublicación: US2017045524A1 16/02/2017

Solicitante:
CRYSTALPLEX CORP [US]

Resumen de: US2017045524A1

Passivated semiconductor nanoparticles and methods for the fabrication and use of passivated semiconductor nanoparticles is provided herein.



traducir


 

Nanoparticulate Compositions for Targeted Delivery of Acid Labile, Lipophilic Prodrugs of Cancer Chemotherapeutics and Their Preparation

NºPublicación: US2017042815A1 16/02/2017

Solicitante:
MCCHESNEY JAMES D [US]
NIKOULIN IGOR [US]
BANNISTER STEVE J [US]
RODENBURG DOUGLAS L [US]
ARBOR THERAPEUTICS LLC [US]

Resumen de: US2017042815A1

In one embodiment, the present application discloses synthetic LDL nanoparticles comprising mixtures of components selected from the group consisting of phospholipids, triglycerides, cholesterol ester and free cholesterol; optionally further comprising an agent selected from the group consisting of natural antioxidants, ubiquinol and vitamin E, and methods for preparing the synthetic nanoparticles. The disclosed synthetic LDL nanoparticles are capable of selectively delivering lipophilic drugs and prodrugs to cellular targets expressing LDL receptors after intra venous injection.



traducir


 

POLYMER-CLAY COMPOSITE AND ORGANOCLAY

NºPublicación: US2017043058A1 16/02/2017

Solicitante:
UNIV SOUTHAMPTON [GB]

Resumen de: US2017043058A1

The invention relates to a polymer-clay composite material comprising clay nanoparticles and a polymer, and wherein (a) the polymer comprises phosphate and/or phosphonate ligands; or (b) the polymer-clay composite further comprises linker molecules comprising a phosphate or phosphonate ligand, wherein the linker molecules are arranged to be anchored to the polymer. The invention further relates to organoclays, BMP-clay composite material. Uses, treatments, and manufacturer of the material are also provided.



traducir


 

NANOSPHERES ENCAPSULATING BIOACTIVE MATERIAL AND METHOD FOR FORMULATION OF NANOSPHERES

NºPublicación: US2017042987A1 16/02/2017

Solicitante:
THE CORP OF MERCER UNIV [US]

Resumen de: US2017042987A1

A method of transdermal delivery of a vaccine, comprising preparing microparticles of encapsulated vaccine by spray drying a mixture of the vaccine and at least one polymer, and injecting the microparticles transdermally using a microneedle delivery apparatus.



traducir


 

TARGETED NANOPARTICLE COMPOSITIONS AND METHODS OF THEIR USE TO TREAT OBESITY

NºPublicación: US2017042870A1 16/02/2017

Solicitante:
THE BRIGHAM AND WOMEN'S HOSPITAL INC [US]
MASSACHUSETTS INST TECHNOLOGY [US]

Resumen de: US2017042870A1

Nanoparticles having a positive feedback delivery system include an agent specific for a target in combination with a target inducing agent. Upon administration to a subject, the targeting moiety on the nanoparticles binds to available targets in the subject. The nanoparticles release the target inducing agent and, optionally, a therapeutic agent, at the site where the nanoparticles bind the target. The inducing agent causes additional targets to be expressed. More nanoparticles bind to the additional, induced targets. By inducing additional targets to be expressed at specific regions in the subject that require treatment, more nanoparticles can bind to the targets in that specific region of interest, increasing the concentration of nanoparticles at a specific area of subject is increased.



traducir


 

METHODS OF PREPARING POLYELECTROLYTE COMPLEX NANOPARTICLES

NºPublicación: US2017042829A1 16/02/2017

Solicitante:
UNIV JOHNS HOPKINS [US]

Resumen de: US2017042829A1

The presently disclosed subject matter provides methods for continuously generating uniform polyelectrolyte complex (PEC) nanoparticles comprising: flowing a first stream comprising one or more water-soluble polycationic polymers at a first variable flow rate into a confined chamber; flowing a second stream comprising one or more water-soluble polyanionic polymers at a second variable flow rate into the confined chamber; and impinging the first stream and the second stream in the confined chamber until the Reynolds number is from about 1,000 to about 20,000, thereby causing the one or more water-soluble polycationic polymers and the one or more water-soluble polyanionic polymers to undergo a polyelectrolyte complexation process that continuously generates PEC nanoparticles. Compositions produced from the presently disclosed methods and a device for producing the compositions are also disclosed.



traducir


 

LIPID NANOPARTICLES FOR DRUG DELIVERY SYSTEM CONTAINING CATIONIC LIPIDS

NºPublicación: US2017042825A1 16/02/2017

Solicitante:
KYOWA HAKKO KIRIN CO LTD [JP]

Resumen de: WO2013089151A1

The present invention provides lipid nanoparticles etc. containing cationic lipids for delivering drugs containing cationic lipids that make it easy to introduce nucleic acids into cells etc., for example. The cationic lipids are represented by formula (I) (in the formula: R1 and R2 are the same or different alkenyls etc.; X3 does not exist, or is an alkyl etc.; X1 and X2 are hydrogen atoms, or together form a single bond or an alkylene; Y1 does not exist, or is an anion; L1 is a single bond etc.; and R3 is an alkyl etc.).



traducir


 

CO-ENCAPSULATION OF ANTIMICROBIALS AND ADJUVANTS IN NANOCARRIERS

NºPublicación: US2017042823A1 16/02/2017

Solicitante:
THE TRUSTEES OF PRINCETON UNIV [US]

Resumen de: US2017042823A1

Microbial infections have become increasingly difficult to treat due to the emergence of drug resistant microbes. Adjunctive therapies can be used to better treat resistant microbes, where multiple drugs are concurrently used to overcome resistant mechanisms and to synergistically treat infections. The practice of adjunctive therapies is limited by the ability to precisely control the pharmacokinetic profiles of the multiple actives. Composite particle-based approaches to enable and enhance adjunctive antimicrobial infections by simultaneous encapsulation and delivery of all components are described herein.



traducir


 

THERAPEUTIC NANOPARTICLES COMPRISING A THERAPEUTIC AGENT AND METHODS OF MAKING AND USING SAME

NºPublicación: US2017042828A1 16/02/2017

Solicitante:
PFIZER [US]

Resumen de: US2017042828A1

The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid, a basic therapeutic agent having a protonatable nitrogen, and a polymer. Other aspects include methods of making and using such nanoparticles.



traducir


 

DELIVERY OF BIOLOGIC THERAPEUTICS

NºPublicación: US2017042816A1 16/02/2017

Solicitante:
ABBOTT CARDIOVASCULAR SYSTEMS INC [US]

Resumen de: US2017042816A1

Formulations and methods are disclosed which provide controlled, sustained release of a biologic therapeutic to a space within the body. More specifically, formulations comprising a plurality of hydrophilic polymer strands, and methods of forming and administering such formulations, are disclosed. In some embodiments, the formulations exhibit a burst release, an initial release, a triphasic release, and release over thirty to ninety days of the biologic therapeutic. In some embodiments, the formulations exhibit reversible precipitation of the biologic therapeutic into precipitates having a diameter of about 50 nm to about 10 μm.



traducir


 

NANOPARTICLES COMPRISING DOCETAXEL FOR TREATING CANCERS HAVING A K-RAS MUTATION

NºPublicación: US2017042855A1 16/02/2017

Solicitante:
BIND THERAPEUTICS INC [US]

Resumen de: US2017042855A1

The present disclosure relates in part to methods of treating cancers having a mutation in a Ras gene in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of a nanoparticle composition, wherein the nanoparticle composition comprises nanoparticles.



traducir


 

NANOLIPIDIC PARTICLE ASSEMBLY POPULATIONS

NºPublicación: US2017042826A1 16/02/2017

Solicitante:
DERMAZONE SOLUTIONS INC [US]

Resumen de: US2017042826A1

Nanolipidic Particles (NLPs) having average mean diameters of 1 nm to 20 nm are made from a precursor solution. NLPs can be loaded with a desired passenger molecule. Assemblies of these particles, called NLP assemblies, result in a vehicle population of a desired size. Single application or multifunction NLP assemblies are made from the loaded NLPs and range in size from about 30 to about 200 nm. A method of using preloaded NLPs to make larger carrier vehicles or a mixed population provides increased encapsulation efficiency. NLPs have application in the cosmetics, pharmaceutical, and food and beverage industries.



traducir


 

FILM DELIVERY SYSTEM FOR ACTIVE INGREDIENTS

NºPublicación: US2017042830A1 16/02/2017

Solicitante:
MONOSOL RX LLC [US]

Resumen de: US2017042830A1

The present invention includes a pharmaceutical-based film system which includes various small-scale forms of pharmaceutically active agents, including testosterone esters, in a film base. Such forms include nanoparticles, microparticles, and combinations thereof. Methods of producing such film and providing a dosage of the pharmaceutical in a film are also provided.



traducir


 

GM3 FUNCTIONALIZED NANOPARTICLES

NºPublicación: US2017042824A1 16/02/2017

Solicitante:
TRUSTEES OF BOSTON UNIV [US]

Resumen de: US2017042824A1

Embodiments disclosed herein relates to ganglioside GM3-containing mixed lipids nanoparticles having an overall size between 60-100 nm, the making thereof and the uses. The nanoparticles selectively targeted to CD169+ expressing cells such as dendritic cells and macrophage. The nano-particles are endocytosed by the CD169+ expressing cells.



traducir


 

NANOPARTICLES FOR TARGETED GENE THERAPY AND METHODS OF USE THEREOF

Nº publicación: US2017042819A1 16/02/2017

Solicitante:
AVRYGEN CORP [US]

Resumen de: US2017042819A1

The present disclosure provides targeted, polymeric nanoparticles which facilitate the delivery of small interfering RNAs, miRNAs and shRNA expressing plasmid DNAs and include an aggregate of nucleic acids and polycationic polymer scaffolds. Methods of making and using such nanoparticles are provided as are methods of treating cancer, including Glioblastoma Multiforme, prostate cancer and melanoma using such nanoparticles.


traducir



 

Página1 de 5 nextPage Mostrar por página

Volver